TY - JOUR
T1 - Opioid-Sparing Effect of Liposomal Bupivacaine and Intravenous Acetaminophen in Colorectal Surgery
AU - Rizk, Elsie
AU - Haas, Eric M
AU - Swan, Joshua T
N1 - Funding Information:
Funding: This work was supported by a research grant from Pacira Pharmaceuticals, Inc, and this grant was used to support fellowship training for Dr Rizk. The funding agency was not involved in the design of the study, collection of the data, analysis of the data, interpretation of the data, nor the development of this manuscript. Author's contributions: E.R. and J.S. conceived the study design. J.S. and E.R. obtained research funding. E.H. provided clinical expertise to guide the study conception and design. E.R. and J.S. developed data collection tools. E.R. collected data. E.R. and J.S. analyzed the data. E.R. drafted the manuscript. All authors revised the manuscript and approved the final version of the manuscript.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/3
Y1 - 2021/3
N2 - Background: This study evaluated the opioid-sparing effect of liposomal bupivacaine and intravenous acetaminophen in colorectal surgery. Materials and methods: This study was a retrospective, 2 × 2 factorial cohort conducted at an academic medical center from May 2016 to February 2018. Patients undergoing open or minimally invasive colorectal resection were included. Exclusion criteria were age <18 y, surgery after second hospital day, ostomy, and allergy to acetaminophen, opioids, or bupivacaine. Intraoperative liposomal bupivacaine and intravenous acetaminophen administration within 18 h after surgery were evaluated. The primary outcome was intravenous morphine milligram equivalents administered within 24 h after surgery. A linear regression model adjusted for American Society of Anesthesiologists score, enhanced recovery after surgery management, open surgery, opioid use before surgery, and height was used for the primary analysis. Results: Among 486 included patients, 193 received both liposomal bupivacaine and intravenous acetaminophen, 93 received liposomal bupivacaine only, 104 received intravenous acetaminophen only, and 96 did not receive either. On average, patients received 21 (SD = 31) morphine equivalents over 24 h. Intraoperative liposomal bupivacaine was associated with a reduction of morphine equivalents (adjusted change −11, 95% CI −17 to −6), but intravenous acetaminophen was not (2, 95% CI −3 to 7). Intraoperative liposomal bupivacaine was associated with a reduction of length of stay (adjusted change = −1.2 d, 95% CI −2.1 to −0.3), but intravenous acetaminophen was not (adjusted change = 1.5 d, 95% CI 0.7 to 2.2). Conclusions: Liposomal bupivacaine was associated with a significant reduction of opioid use within 24 h after colorectal surgery, but intravenous acetaminophen was not.
AB - Background: This study evaluated the opioid-sparing effect of liposomal bupivacaine and intravenous acetaminophen in colorectal surgery. Materials and methods: This study was a retrospective, 2 × 2 factorial cohort conducted at an academic medical center from May 2016 to February 2018. Patients undergoing open or minimally invasive colorectal resection were included. Exclusion criteria were age <18 y, surgery after second hospital day, ostomy, and allergy to acetaminophen, opioids, or bupivacaine. Intraoperative liposomal bupivacaine and intravenous acetaminophen administration within 18 h after surgery were evaluated. The primary outcome was intravenous morphine milligram equivalents administered within 24 h after surgery. A linear regression model adjusted for American Society of Anesthesiologists score, enhanced recovery after surgery management, open surgery, opioid use before surgery, and height was used for the primary analysis. Results: Among 486 included patients, 193 received both liposomal bupivacaine and intravenous acetaminophen, 93 received liposomal bupivacaine only, 104 received intravenous acetaminophen only, and 96 did not receive either. On average, patients received 21 (SD = 31) morphine equivalents over 24 h. Intraoperative liposomal bupivacaine was associated with a reduction of morphine equivalents (adjusted change −11, 95% CI −17 to −6), but intravenous acetaminophen was not (2, 95% CI −3 to 7). Intraoperative liposomal bupivacaine was associated with a reduction of length of stay (adjusted change = −1.2 d, 95% CI −2.1 to −0.3), but intravenous acetaminophen was not (adjusted change = 1.5 d, 95% CI 0.7 to 2.2). Conclusions: Liposomal bupivacaine was associated with a significant reduction of opioid use within 24 h after colorectal surgery, but intravenous acetaminophen was not.
KW - Colorectal surgery
KW - Enhanced recovery after surgery
KW - Intravenous acetaminophen
KW - Liposomal bupivacaine
KW - Opioids
KW - Pain management
UR - http://www.scopus.com/inward/record.url?scp=85092500330&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092500330&partnerID=8YFLogxK
U2 - 10.1016/j.jss.2020.09.002
DO - 10.1016/j.jss.2020.09.002
M3 - Article
C2 - 33051063
SN - 0022-4804
VL - 259
SP - 230
EP - 241
JO - The Journal of surgical research
JF - The Journal of surgical research
ER -